Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1988 Jun 4;296(6636):1557–1561. doi: 10.1136/bmj.296.6636.1557

Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study

C P Thakur, M Kumar, P Kumar, B N Mishra, A K Pandey
PMCID: PMC2545950  PMID: 2840172

Abstract

The efficacy and safety of six regimens of treatment for kala-azar (visceral leishmaniasis) with sodium stibogluconate were evaluated in a prospective randomised study to ascertain the optimal treatment for Indian patients. Altogether 371 patients with kala-azar were randomised to receive sodium stibogluconate intramuscularly at a dose of 10 mg/kg body weight/day for 20 or 40 days (groups A and A1, respectively), 15 mg/kg body weight/day for 20 or 40 days (groups B and B1, respectively), or 20 mg/kg body weight/day for 20 or 40 days (groups C and C1, respectively). Patients were examined blind before and at the end of treatment and every month for six months. The number of patients who were apparently cured—that is, those whose temperature had returned to normal at the end of their regimen of treatment—was 45 (78%) in group A, 53 (87%) in group A1, 50 (81%) in group B, 60 (95%) in group B1, 58 (92%) in group C, and 62 (97%) in group C1.

At six months 62 patients (97%) in group C1, 51 (81%) in group C, 54 (86%) in group B1, 42 (68%) in group B, 45 (74%) in group A1, and 33 (57%) in group A had not relapsed and were cured as confirmed by a bone marrow aspirate free of parasites. The differences between groups C1 and C, B1 and B, and A1 and A were significant. Logistic regression of the proportion cured with the dose and length of treatment showed that both factors were significant in improving the rate of cure; the highest dose for the longer time (group C1) had the best rate of cure. One patient in group C1, 12 in group C, nine in group B1, 18 in group B, 15 in group A1, and 23 in group A were cured with extended courses of 20 mg sodium stibogluconate. One patient in each of groups C1, B, A1, and A became unresponsive to antimony and were cured with pentamidine. One patient in each of groups C1, B, and A became unresponsive to both antimony and pentamidine. The patients tolerated the longer duration of treatment safely, and side effects were minor.

Sodium stibogluconate should be given intramuscularly in the dosage of 20 mg/kg for at least 40 days, when patients should be assessed for further treatment if necessary. Such a regimen should achieve the highest rate of cure with low toxicity and low rates of relapse and unresponsiveness.

Full text

PDF
1557

Images in this article

1558p1558-a
on p.1558

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anabwani G. M., Ngira J. A., Dimiti G., Bryceson A. D. Comparison of two dosage schedules of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya. Lancet. 1983 Jan 29;1(8318):210–213. doi: 10.1016/s0140-6736(83)92588-6. [DOI] [PubMed] [Google Scholar]
  2. Bryceson A. D., Chulay J. D., Mugambi M., Were J. B., Gachihi G., Chunge C. N., Muigai R., Bhatt S. M., Ho M., Spencer H. C. Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine. Trans R Soc Trop Med Hyg. 1985;79(5):705–714. doi: 10.1016/0035-9203(85)90199-3. [DOI] [PubMed] [Google Scholar]
  3. Chulay J. D., Bhatt S. M., Muigai R., Ho M., Gachihi G., Were J. B., Chunge C., Bryceson A. D. A comparison of three dosage regimens of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya. J Infect Dis. 1983 Jul;148(1):148–155. doi: 10.1093/infdis/148.1.148. [DOI] [PubMed] [Google Scholar]
  4. Jha T. K., Sharma V. K. Prolonged sodium stibogluconate therapy in Indian kala-azar. J Assoc Physicians India. 1986 Jul;34(7):469–471. [PubMed] [Google Scholar]
  5. Kager P. A., Rees P. H., Manguyu F. M., Bhatt K. M., Wellde B. T., Hockmeyer W. T., Lyerly W. H., Jr Clinical, haematological and parasitological response to treatment of visceral leishmaniasis in Kenya. A study of 64 patients. Trop Geogr Med. 1984 Mar;36(1):21–35. [PubMed] [Google Scholar]
  6. Rees P. H., Keating M. I., Kager P. A., Hockmeyer W. T. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet. 1980 Aug 2;2(8188):226–229. doi: 10.1016/s0140-6736(80)90120-8. [DOI] [PubMed] [Google Scholar]
  7. Thakur C. P. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg. 1984;78(3):391–398. doi: 10.1016/0035-9203(84)90131-7. [DOI] [PubMed] [Google Scholar]
  8. Thakur C. P. Harmful effect of high stibogluconate treatment of kala-azar in India. Trans R Soc Trop Med Hyg. 1986;80(4):672–673. doi: 10.1016/0035-9203(86)90178-1. [DOI] [PubMed] [Google Scholar]
  9. Thakur C. P., Kumar M., Singh S. K., Sharma D., Prasad U. S., Singh R. S., Dhawan P. S., Achari V. Comparison of regimens of treatment with sodium stibogluconate in kala-azar. Br Med J (Clin Res Ed) 1984 Mar 24;288(6421):895–897. doi: 10.1136/bmj.288.6421.895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Thakur C. P. Treatment of visceral leishmaniasis in Bihar. Trop Doct. 1986 Oct;16(4):146–147. doi: 10.1177/004947558601600402. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES